Gene expression profiling of L-540, SUP-HD1, KM-H2 and L-428 Hodgkin lymphoma cell lines after in vitro and in vivo treatment with the dual PI3K/ERK inhibitor AEZS-136 [2 hours]

ABSTRACT: Disease relapse and resistance to chemotherapy represent challenging issues in a subset of Hodgkin Lymphoma (HL) patients. Activity and mechanism(s) of action of a novel PI3K/ERK dual inhibitor AEZS-136 (Æterna Zentaris GmbH, Germany, EU) were examined in L-540, SUP-HD1, KM-H2 and L-428 cell lines. Despite exposure to AEZS-136 induced a significant cell growth inhibition (range, 30-80%), levels of caspase-independent cell death and mitochondrial dysfunction, were only observed in L-540 (62 ±9 vs 14 ±3%, P ≤.0001) and SUP-HD1 (46 ±2% vs 15 ±2%, P ≤.0001) cells. Gene expression profiling indicated that the effects of AEZS-136 treatment are associated with the modulation of cell cycle and cell death pathways. Exposure to AEZS-136 resulted in sustained production of reactive oxygen sp

ORGANISM(S): Homo sapiens

SUBMITTER: Giuliano Stirparo 

PROVIDER: E-GEOD-71150 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress